To investigate the effect and the possible mechanism underlying the promotional effect of Astragalus membranaceus and Panax notoginseng on the transformation of bone narrow stem cells and proliferation of EPC.

To investigate the expression of human coagulation factor IX (hFIX) gene in human umbilical cord blood (CB) CD34+ cells which was transfected with recombinant adeno-associated virus 2 (rAAV-2).

To explore and establish a new method of isolation, culture, and identification of adult epidermal stem cell in vitro for the provision of seed-cells in tissue engineering of skin.

To follow the fate of murine epidermal stem cells (ESCs) seeded in a syngeneic dermal equivalent implanted in vivo.

To investigate the feasibility of transplanted endothelial progenitor cells to ischemic flap with increased neovascularization and augmented the survival areas.

To review the latest development of amniotic membrane and its application.

To review the research progress of osteoblast extracellular matrix (ECM) and its application in bone tissue engineering.

To explore the effect of age and gene therapy on the differentiation of marrow mesenchymal stem cells (MSCs) of the rats.

To construct the Gcn5 shRNA plasmids and to explore the Gcn5 shRNA role in histone acetylation modification with the differentiation of stem cells.

Hematopoietic stem cell (HSC) is the first discovered and well studied tissue stem cell. HSC transplantation has been successfully applied to cure a variety of diseases of hematological and immunological systems. It has long believed that HSC and angioblast come from the common stem cell, the hemangioblast. Recently, HSC has been demonstrated to be able to differentiate into vascular endothelial cells. In animal in vivo models, HSC transplantation can promote angiogenesis and improve limb ischemia. Several pilot clinical studies have shown that transplantation of bone marrow and granulocyte colony stimulating factor mobilized peripheral blood HSC promoted vascular reconstitution in ischemic limbs. Umbilical cord blood has been an important source of HSC for clinical transplantation. Animal studies have demonstrated the efficiency of cord blood HSC transplantation in improving critical limb ischemia. These studies have provided evidences that HSC can be used for the treatment of vascular diseases.

Cartilage is a tough, elastic, and fibrous connective tissue, composed of chondrocyte and extracellular matrix (ECM) structural entity. Because of the poor self-regeneration capabilities of chondrocytes, cell transplantation is necessanry once the cartilage is damaged. Traditionally autologous chondrocytes implantation is applied at the damage site, which has many problems such as the losing of its primary characteristics. A well-defined and efficient protocol to direct the differentiation of embryonic stem cells into the chondrocyte will provide a novel choice for cartilage repair. This article reviews some major progresses in this field.

At present, no effective therapeutic option for ischemic heart disease is available. The majority of the data on stem cell transplantation coming from preclinical animal studies and clinical research in small scale demonstrate that it may improve cardiac function. However, serious questions about its safety have yet to be answered.

To evaluate the possibility that using intracoronary delivery of autologus bone marrow-derived mesenchymal stem cells (MSCs) to improve the cardiac function after acute myocardial infarction (AMI) in miniature pig.

To investigate the feasibility that transforming growth factor-beta1 (TGF-beta1) -loaded fibrin sealant (FS) promotes bone marrow mesenchymal stem cells (BMSCs) to create tissue engineering cartilage in vivo.

To verify the hypothesis that selected nestin positive cells derived from human fetal pancreas (according as medical ethnics) have surface markers similar to bone marrow mesenchymal stem cells (MSCs), and that these cells have multilineage potential.

To investigate whether human adipose derived adult stem (hADAS) cells can differentiate into endothelial cells.

To construct artificial rabbit corneas with autologous skin epidermal stem cells and allogenic stromal cells in vitro and promote healing of corneal wounds.

To explore the possibility that using the bovine corneal stroma to provide a suitable carrier on which the cells can grow for tissue engineering cornea.

To study differentiation of human bone marrow-derived mesenchymal stem cells (BDMSC) into blood vessel endothelial cells for ideal cell origin of complex organ tissue engineering vascularization and injured tissue repairing by cell transplantation.

Seed cells are prerequisite for reconstruction of artificial tissues/organs by tissue engineering approach. It has been widely accepted that stem cells are the best candidate for tissue engineering. The successful repair of tissue damages with adult stem cell mediated tissue engineering therapy in both animal models and patients has demonstrated the feasibility of using this technique for tissue/organ regeneration. Further studies in allogeneic adult stem cells and the establishment of universal embryonic stem cells will be critical for the industrialization of tissue engineering in future.